Navigation Links
Advanced Life Sciences Announces Second Quarter 2008 Financial Results
Date:8/14/2008

nism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials, the adequacy of our clinical results, the timing and terms of any commercial partnership, and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Tenn. , May 4, 2015   ... developed a significantly better computer tool for finding ... many cancers but were difficult to identify with ... scientific journal Nature Methods . ... for Copy Number Segmentation by Regression Tree in ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... --  Tocagen Inc. , a clinical-stage immuno-oncology company, ... investigational studies were presented at the 11 th ... Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section ... Washington, D.C. In addition, Tocagen ... and continues to advance towards initiation of a ...
Breaking Biology Technology:Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
... ... enhance greenhouse gas reduction on the local level , , ... Marlborough, MA (PRWEB) October 24, 2009 -- Over forty employees at ... International Day of Climate Action , October 24, 2009. Climate Change awareness actions such as ...
... - Dr. Brad Thompson, President and CEO of Oncolytics ... present a corporate overview of the Company at the ... 28, 2009 at 3:00 p.m. PT. The conference will ... on October 28 and 29, 2009. , A live ...
... YORK, Oct. 23 Pulmo BioTech Inc. (OTC ... that it will ultimately receive at least $3.3 ... the previously announced non-binding letter of intent with ... its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development ...
Cached Biology Technology:Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action, October 24, 2009 2Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action, October 24, 2009 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 2Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 3Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market 4
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... trackway with 12 consecutive prints provides the most compelling ... trackway, located in La Virgen del Campo track site ... continuous record of swimming by a non-avian therapod dinosaur. ... Patrimonio Paleontológico de La Rioja, La Rioja, Spain, discovered ...
... new gene therapy can nearly eliminate arthritis pain, and ... to a study published today in the journal Arthritis ... they are the first genetically engineered to develop osteoarthritis ... some more likely to develop the disease, the authors ...
... of Central and South America conduct spectacular predatory raids containing ... bodies to plug potholes in the trail leading back to ... be delivered to the developing young at maximum speed. , ... trail of forager traffic, along which prey-laden foragers run back ...
Cached Biology News:Definitive evidence found of a swimming dinosaur 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 2Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 3Experimental gene therapy 'abolishes' arthritis pain and lessens joint damage 4Ants show us how to make super-highways 2
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... Preparation Note: Prepared by a modification ... et al., Biotechnol. Bioeng., ... One unit will yield an A ... ml of water (1 cm light ...
... Cleland’s Reagent, Immobilized White solid. PACKAGED ... of DTT on polyacrylamide resin with applications similar ... 233153 , 233156 , and 233155 ... soluble components are added to the system. REDUCTACRYL™ ...
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
Biology Products: